Follow-up Study Underway with Results Expected in Q3/2025

 

WINNIPEG – TheNewswire - July 28, 2025 - Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today announced promising results of the European pilot study of AviPhage, its bacteriophage-based poultry health product, in broiler chickens (see press release April 30, 2025).

 

The purpose of this pilot study was to generate data on the efficacy of AviPhage on European poultry and evaluate the study protocol in a working barn setting. The study compared the AviPhage-Treated Study Group to the Control Group that received preventative standard antibiotics in respect to lowering E. coli bacteria levels. Overall, the study results show that AviPhage was comparable to or outperformed antibiotics in key performance indicators.

 

AviPhage is a bacteriophage-based poultry solution that has been developed by Cytophage to promote gut health, increase bird weight, improve feed conversion ratio, decrease signs of disease, and reduce mortality, becoming an alternative to preventative antibiotic use.

 

Results Highlights:

 

• E. COLI CONTAINMENT: AviPhage effectively restricted E. coli from migrating from the intestines into the bloodstream, tissues and organs - critical to reducing disease progression.  

• EFFECTIVE MORTALITYCONTROL WITHOUT ANTIBIOTICS: Mortality in the AviPhage group was statistically equivalent to that of the standard antibiotic-treated control group - a meaningful result demonstrating AviPhage’s ability to protect bird health without relying on antibiotics and supporting its potential as a safer alternative. 

• IMPROVED WEIGHT UNIFORMITY: AviPhage-treated birds showed more consistent individual weights, providing producers with greater yield predictability. 

• BIRD HEALTH: Chickens treated with AviPhage remained healthy throughout the trial, without signs of E. coli-related illness, and without the use of antibiotics. 

 

Next Steps:

 

The follow-up trial, launched in early July, incorporated enhanced study design and operational controls. The study compares AviPhage-treated birds with an untreated, non-antibiotic control group and is expected to conclude in August. Results are anticipated thereafter.

 

“We are highly encouraged by these outcomes,” said Dr. Steven Theriault, CEO of Cytophage. “AviPhage kept birds healthy, controlled E. coli, and matched antibiotic-level mortality rates - all without antibiotics. We are confident AviPhage will demonstrate further advantages under optimized conditions.”

  

About Cytophage 

Cytophage Technologies (TSXV:CYTO / FSE: 70G) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular or organism-level defences. They are nature’s version of antibiotics. 

 

Cytophage is improving bacteria’s natural predators with environmental as well as genetic modifications to bring safe and toxin-free killer solutions to large addressable markets with an initial focus on animal health which offers a fast-track to near-term revenue. As a leading bacteriophage manufacturer in Canada and powered by a large library of strains, Cytophage is committed to addressing the global challenge of antibiotic resistance (AMR).

 

The WHO predicts that AMR will be the leading cause of human mortality by 2050. Many countries have already banned or limited preventative antibiotic use in animal production including 27 EU countries, US, Canada, Brazil, Bangladesh, India and Mexico. In addition to that, consumers all over the world are demanding organic and antibiotic-free products. 

 

Cytophage is using a de-risked and patented technology to advance innovative and cost competitive products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.  

 

For more information on Cytophage Technologies and its innovative work in bacteriophage therapy, please visit www.cytophage.com.

For further information please contact:  

Heather Medwick, Chief Operating Officer 
heather@cytophage.com | 431 388 8873 

Cytophage Investor Alerts: https://cytophage.com/subscribe

 

Cautionary Statement on Forward-Looking Information 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cytophage to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Cytophage’s Filing Statement dated January 30, 2024, which is available for view on SEDAR+ at www.sedarplus.ca. These risks include but are not limited to, the risks associated with the bacteriophage industry, such as operational risks in development or capital expenditures, the uncertainty of extensive regulatory approval requirements, government regulations, protection of intellectual property, product liability and rapid technological advancements. Forward-looking statements contained herein are made as of the date of this press release, and Cytophage disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.  

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.